SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-020785
Filing Date
2024-05-20
Accepted
2024-05-20 17:27:35
Documents
14
Period of Report
2024-05-20
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41464
2 ex4-1.htm EX-4.1 15303
  Complete submission text file 0001493152-24-020785.txt   237075

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT immx-20240520.xsd EX-101.SCH 3015
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT immx-20240520_lab.xml EX-101.LAB 34240
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT immx-20240520_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3814
Mailing Address 10573 W. PICO BLVD. #58 LOS ANGELES CA 90064
Business Address 11400 WEST OLYMPIC BLVD. SUITE 200 LOS ANGELES CA 90064 (888) 958-1084
Immix Biopharma, Inc. (Filer) CIK: 0001873835 (see all company filings)

IRS No.: 454869378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41159 | Film No.: 24965981
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)